Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Retained Earnings: 2021-2025

Historic Retained Earnings for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to -$27.2 million.

  • Krystal Biotech's Retained Earnings rose 87.96% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.2 million, marking a year-over-year increase of 87.96%. This contributed to the annual value of -$180.7 million for FY2024, which is 33.04% up from last year.
  • Latest data reveals that Krystal Biotech reported Retained Earnings of -$27.2 million as of Q3 2025, which was up 74.45% from -$106.6 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Retained Earnings high stood at -$27.2 million for Q3 2025, and its period low was -$359.3 million during Q2 2023.
  • Over the past 3 years, Krystal Biotech's median Retained Earnings value was -$253.3 million (recorded in 2024), while the average stood at -$222.0 million.
  • As far as peak fluctuations go, Krystal Biotech's Retained Earnings tumbled by 119.19% in 2022, and later soared by 87.96% in 2025.
  • Krystal Biotech's Retained Earnings (Quarterly) stood at -$140.8 million in 2021, then slumped by 99.43% to -$280.8 million in 2022, then climbed by 3.89% to -$269.8 million in 2023, then soared by 33.04% to -$180.7 million in 2024, then soared by 87.96% to -$27.2 million in 2025.
  • Its Retained Earnings stands at -$27.2 million for Q3 2025, versus -$106.6 million for Q2 2025 and -$144.9 million for Q1 2025.